Treatment of Heavy Menstrual Bleeding in Women
For symptomatic heavy menstrual bleeding in women, first-line medical management should be the levonorgestrel-releasing intrauterine system (LNG-IUD), combined oral contraceptives, or tranexamic acid, with NSAIDs as adjunctive therapy during bleeding days. 1, 2
First-Line Treatment Options
The most recent guidelines establish a clear hierarchy for medical management:
Levonorgestrel-Releasing IUD (52 mg)
- Most effective first-line option with 71-95% reduction in menstrual blood loss 3, 4
- Efficacy comparable to endometrial ablation
- Safe and effective across all reproductive ages, including adolescents 5
- Works primarily at the endometrial level with minimal systemic absorption
- Does not compromise future fertility
Combined Oral Contraceptives
- Reduce bleeding symptoms effectively 2
- Can be used in standard cyclic or extended/continuous regimens
- Appropriate for women without contraindications to estrogen
Tranexamic Acid
- Nonhormonal alternative achieving 40.4% reduction in menstrual blood loss versus 8.2% with placebo 6
- Dose: 3.9 g/day for up to 5 days per menstrual cycle
- Significantly improves quality of life measures
- Critical caveat: Contraindicated in women with active thromboembolic disease or history of thrombosis 7
- Should be avoided in women with cardiovascular disease (e.g., SCAD) due to MI and thrombosis risk 3
NSAIDs (Adjunctive)
- Use for 5-7 days during bleeding episodes 7, 1, 7
- Options include mefenamic acid, ibuprofen, indomethacin, or diclofenac
- All NSAIDs except one study showed statistically significant reductions in menstrual blood loss 7
- Can be combined with hormonal methods
- Avoid in women with cardiovascular disease 3
Second-Line Treatment Options
When first-line therapies fail or are contraindicated:
GnRH Antagonists (Oral)
- Examples: elagolix, linzagolix, relugolix 2
- Reduce both bleeding symptoms and fibroid volume
- Must be combined with low-dose estrogen and progestin to mitigate hypoestrogenic effects (hot flushes, bone loss, hypertension) 2
- FDA-approved for fibroid-related heavy menstrual bleeding
- Symptoms recur rapidly after cessation
GnRH Agonists (Parenteral)
- Example: leuprolide acetate 2
- Effective for reducing bleeding and tumor volume
- Commonly used short-term before surgery
- Similar hypoestrogenic side effects as antagonists
Progestin-Only Options
- Depot medroxyprogesterone acetate (DMPA)
- Oral progestins (continuous)
- Cyclic oral progestin reduces bleeding by 87% 3
Acute Heavy Menstrual Bleeding Management
For hemodynamically unstable patients or acute bleeding:
High-Dose Hormonal Regimens
- Combined oral contraceptives: multidose regimen 8
- High-dose oral or injectable progestin-only medications 3
- Treatment decisions should be based on hemoglobin levels and need for hospitalization 9
Parenteral Estrogen
- For acute bleeding with hemodynamic instability 8
Antifibrinolytics
Critical Clinical Decision Points
Rule Out Underlying Pathology First
Before initiating treatment, evaluate for:
- Pregnancy (mandatory in all reproductive-age women) 3
- Structural abnormalities: fibroids, polyps, adenomyosis 7, 1, 7
- Bleeding disorders (especially in adolescents—13.7% prevalence) 10, 5, 11, 9
- Thyroid disorders 1
- Medication interactions, particularly anticoagulation 1
- STDs or PID in IUD users 7, 1
Assessment of Hemodynamic Stability
- Check orthostatic blood pressure and pulse 10
- Bleeding saturating large pad/tampon hourly for ≥4 hours warrants urgent evaluation 3
- Measure hemoglobin and serum ferritin 10, 9
Special Populations Requiring Modified Approach
Women with Bleeding Disorders:
- All hormonal methods and tranexamic acid are appropriate 8, 12
- LNG-IUD is superior and should be considered definitive long-term maintenance 5, 12
- Consider phase-based approach: acute control → bridging stabilization → long-term maintenance 12
- Coordinate care with hematology 10
Women on Anticoagulation:
- Progestin-only methods preferred 8
- Consider GnRH agonists 8
- Avoid NSAIDs and tranexamic acid due to thrombosis risk
Women with Cardiovascular Disease (e.g., SCAD):
- Avoid NSAIDs and tranexamic acid (MI/thrombosis risk) 3
- LNG-IUD 20 μg/day is most effective option (71-95% reduction) 3
- Lower-dose LNG-IUD 14 μg/day may offer advantages with less systemic absorption 3
- Cyclic oral progestin acceptable despite theoretical concerns 3
- Consider endometrial ablation if hormones contraindicated 3
Adolescents:
- 85% report HMB during adolescence 11
- Screen for bleeding disorders (higher prevalence) 10, 5, 9
- Hypothalamic-pituitary-ovarian axis immaturity most common cause (63.9%) 9
- LNG-IUD safe and effective in this age group 5
Common Pitfalls to Avoid
Do not use aspirin for heavy menstrual bleeding—it increases blood loss 7
Do not delay specialist referral when bleeding disorders suspected—coordinate with hematology early 10
Do not use tranexamic acid in women with thrombotic risk or cardiovascular disease 7, 3
Do not recommend hormone-free intervals during first 21 days of extended CHC use or more than once monthly (reduces contraceptive effectiveness) 1, 7
Do not assume LNG-IUD insertion is appropriate during acute bleeding—it should be considered definitive long-term maintenance after bleeding control and hematologic recovery 12
Do not overlook iron deficiency—54% of women with VWD had iron deficiency despite treatment 11
Treatment Algorithm for Cu-IUD Users with Heavy Bleeding
This specific scenario has detailed guidance:
- Counsel before insertion about expected bleeding patterns (first 3-6 months) 7
- If bleeding develops, rule out: IUD displacement, STD, pregnancy, new pathologic conditions 7, 1, 7
- If no pathology found: NSAIDs 5-7 days during bleeding 7, 1, 7
- If bleeding persists: counsel on alternative methods and offer method change 7
Surgical Considerations
Reserve surgery for:
- Women with pelvic pathology requiring intervention 4
- Failure of medical therapy 4
- Hemodynamic instability despite medical management 10
Surgical options include: